AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

Research and development expenses for the first quarter of 2025 increased to $9.1 million from $7.7 million for the prior ...

ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a ...

CG Oncology Inc.’s latest research effort to treat bladder cancer is impressing investors.The Irvine-based biopharmaceutical ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...

An investigator reported updated findings from the phase 2/3 study QUILT 3.032 using a July 15, 2024 data cutoff.

The safety profile of cretostimogene was reported to be well-tolerated, with no grade 3 or greater treatment-related adverse ...

TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the ...

Lightweight, high-precision AI model effectively overcomes two major barriers to AI deployment in bladder cancer care: Low detection rates for difficult-to-identify lesions. Prohibitive computational ...

BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.